Skip to main content

Table 2 Incidence of adverse events per patient

From: Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors

  All Patients (N = 30)
Patients with any treatment-emergent AE, n (%) 30 (100)
Patients with any treatment-emergent serious AE, n (%) 12 (40)
Patients with a grade 3 treatment-related AE, n (%) 0
Patients with a grade 4 treatment-related AE, n (%) 0
Patients with a grade 5 treatment-related AE, n (%) 1 (3)
Incidence of treatment-related AEs, n (%) 18 (60)
 Fatigue, all grades 4 (13)
  Grade 1 3 (10)
  Grade 2 1 (3)
 Infusion-related reaction, all grades 2 (7)
  Grade 1 2 (7)
 Pyrexia, all grades 2 (7)
  Grade 1 2 (7)
 Decreased appetite, all grades 2 (7)
  Grade 1 2 (7)
 Hypophosphataemia, all grades 2 (7)
  Grade 2 2 (7)
  1. AE adverse event
  2. *AEs occurring in in ≥5% of patients are shown